Blue Crest Capital Management LTD Neurocrine Biosciences Inc Transaction History

Blue Crest Capital Management LTD

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$94.11 - $123.02 $282,330 - $369,060	3,000 New	3,000 $303,000
Q4 2019 Feb 14, 2020	SELL	$86.8 - $118.57 $338,086 - $461,830	-3,895 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$83.82 - $101.5 $326,478 - $395,342	3,895 New	3,895 $351,000
Q4 2018 Feb 14, 2019	SELL	$68.32 - $124.36 $1.47 Million - $2.67 Million	-21,468 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$98.88 - $125.85 $2.12 Million - $2.7 Million	21,468 New	21,468 $2.64 Million
Q1 2018 May 15, 2018	SELL	$75.88 - $92.43 $1.3 Million - $1.59 Million	-17,176 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$58.53 - $77.59 $468,532 - $621,107	-8,005 Reduced 31.79%	17,176 $1.33 Million
Q3 2017 Nov 14, 2017	BUY	$47.97 - $61.28 $1.21 Million - $1.54 Million	25,181	25,181 $1.54 Million

625

94.2M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Blue Crest Capital Management LTD, based on Form 13F filings with the SEC.

Stay updated on Blue Crest Capital Management LTD with notifications on news.